Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin

Antimicrob Agents Chemother. 2004 Mar;48(3):1061-4. doi: 10.1128/AAC.48.3.1061-1064.2004.

Abstract

For the treatment of rabbit endocarditis, dalbavancin given once daily (10 mg/kg of body weight for 4 days) or as a single 40-mg/kg dose was active against Staphylococcus aureus with or without reduced susceptibility to glycopeptides, as expected from its good in vitro activity, even in broth supplemented with 90% serum and given its prolonged elimination half-life.

MeSH terms

  • Animals
  • Area Under Curve
  • Colony Count, Microbial
  • Drug Resistance, Bacterial
  • Endocarditis, Bacterial / drug therapy*
  • Endocarditis, Bacterial / microbiology
  • Female
  • Glycopeptides / therapeutic use*
  • Half-Life
  • Rabbits
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology
  • Teicoplanin / pharmacology*
  • Vancomycin Resistance*

Substances

  • Glycopeptides
  • Teicoplanin
  • dalbavancin